logo

25.59

25.59 (0.13%)

As of Feb 09, 2023

Syndax Pharmaceuticals Inc [SNDX]

Source: 

Company Overview

Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies. Our two lead product candidates are revumenib (SNDX-5613), and axatilimab (SNDX-6352).

CountryUnited States
Headquarterswalthammassachusetts
Phone Number781-419-1400
Industry
manufacturing
CEOMichael A. Metzger
Websitewww.syndax.com